Ignite Creation Date:
2025-12-25 @ 2:10 AM
Ignite Modification Date:
2026-03-10 @ 11:32 PM
Study NCT ID:
NCT01356160
Status:
COMPLETED
Last Update Posted:
2014-02-03
First Post:
2011-05-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Sponsor:
Gilead Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hepatitis C, Chronic | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hepatitis C | View |
| None | HCV | View |
| None | Rapid Virologic Response | View |
| None | Sustained Virologic Response | View |
| None | Direct Acting Antiviral | View |
| None | Combination Therapy HCV RNA | View |
| None | Protease inhibitor | View |
| None | Treatment naïve | View |
| None | GS-5885 | View |
| None | GS-9451 | View |